1,5-anhydroglucitol (GlycoMark™) as a marker of short-term glycemic control and glycemic excursions

被引:154
作者
Dungan, Kathleen M. [1 ]
机构
[1] Ohio State Univ, Columbus, OH 43210 USA
关键词
1,5-anhydroglucitol; A1C; glucose; glycemic control; glycemic excursion; glycemic variability; post-prandial glucose;
D O I
10.1586/14737159.8.1.9
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
1,5-anhydroglucitol (1,5-AG) is a validated marker of short-term glycemic control. It is a metabolically inert polyol that competes with glucose for reabsorption in the kidneys. Otherwise stable levels of 1,5-AG are rapidly depleted as blood glucose levels exceed the renal threshold for glucosuria. 1,5-AG more accurately predicts rapid changes in glycemia than hemoglobin A1C (A1C) or fructosamine. It is also more tightly associated with glucose fluctuations and postprandial glucose. Thus, 1,5-AG may offer complementary information to A1C. This review will summarize the limitations of current methods of assessing glycemic control, assess the data to support 1,5-AG as a glycemic marker and highlight the scenarios by which 1,5-AG may fill the gap in assessing glycemic control.
引用
收藏
页码:9 / 19
页数:11
相关论文
共 92 条
[1]  
AKANUMA Y, 1988, DIABETOLOGIA, V31, P831
[2]  
AKUTSU T, 2007, AM DIAB ASS 67 ANN S
[3]  
Am Diabetes Assoc, 2006, DIABETES CARE, V29, pS4
[4]  
[Anonymous], 1995, DIABETES, V44, P968
[5]  
[Anonymous], 2007, DIABETES CARE, DOI DOI 10.2337/DC07-S004
[6]  
BERGENSTAL R, 2000, DIABETES ED, V26, P81
[7]   Glucose tolerance and cardiovascular mortality -: Comparison of fasting and 2-hour diagnostic criteria [J].
Borch-Johnsen, K ;
Neil, A ;
Balkau, B ;
Larsen, S ;
Nissinen, A ;
Pekkanen, J ;
Tuomilehto, J ;
Jousilahti, P ;
Lindstrom, J ;
Pyörälä, M ;
Pyörälä, K ;
Eschwege, E ;
Gallus, G ;
Garancini, MP ;
Bouter, LM ;
Dekker, JM ;
Heine, RJ ;
Nijpels, HG ;
Stehouwer, CDA ;
Feskens, EJM ;
Kromhout, D ;
Peltonen, M ;
Pajak, A ;
Eriksson, J ;
Qiao, Q .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (03) :397-405
[8]  
Braatvedt GD, 1997, NEW ZEAL MED J, V110, P459
[9]  
BRAATVEDT GD, 1997, NZ MED J, V12, P459
[10]  
Buse John B, 2003, Diabetes Technol Ther, V5, P355, DOI 10.1089/152091503765691839